As we all wearily trawl through the huge mountain of data for ASCO 2017, what stands out – and more importantly – what matters and why?
Before we get into our in-depth coverage based on the tumour type, target and modality landscapes, I wanted to take a moment to highlight five key abstracts that stood out for me as worthy of checking out in more detail once we get to Chicago.
Interestingly, only one of them is from big Pharma!
At least one had some negatives associated with it as we’re not all happy clappy everything is great enthusiasts here at BSB. We do try to be fair minded and objective as possible about data.
So what’s in store and why do these five matter?